Intense competition in CRO has reduced gross margin. Sunlight Nuohe is entering the animal health field to seek new growth points.

① Sunshine Nuohuo has experienced growth in revenue and net income in the first three quarters of this year compared to previous years, but intense competition in the industry has led to a decline in gross margin, and the chairman revealed that the company is increasing its investment in research and development. ② To seek new growth points, Sunshine Nuohuo is expanding its CRO business from the human pharmaceutical field to the animal health field by establishing subsidiaries, and has signed service orders with several medium and large animal pharmaceutical companies.

cls.cnDec 2 02:59 ET

Tasly Pharmaceutical Group: Some products are priced down, leading to a decrease in Q3 gross margin. All parties are actively promoting the trade with China Resources Sanjiu Medical & Pharmaceutical | Straight to the earnings conference

① Due to the overall low prosperity in the pharmaceutical commerce industry, the company's revenue in this sector declined in the third quarter of this year; although revenue in the pharmaceutical industry sector grew year-on-year, the price reduction of some products led to a decrease in gross margin, and the company expects that the gross margin may remain stable in the future. ② Regarding the equity trade matter of the company's major shareholder with china resources sanjiu medical & pharmaceutical, the company's general manager Cai Jinyong stated that the company and relevant parties are actively promoting the various aspects of this trade.

cls.cnNov 27 09:29 ET

Clinical results did not meet expectations. Tasly Pharmaceutical Group suspends the eight-year development "marathon" of the new anti-cancer drug | Summary of the announcement.

① Tasly Pharmaceutical Group announced the suspension of the research and development of its anmeimu monoclonal antibody. Since its approval in 2016, the drug has reached the IIb phase of clinical research; ② According to the clinical research results, the efficacy of anmeimu monoclonal antibody did not meet expectations, and other EGFR monoclonal antibody biosimilar drugs face fierce competition; ③ This project also involves Sino Biopharmaceutical's equity participation, with Tasly Pharmaceutical Group and Sino Biopharmaceutical respectively recognizing an impairment loss of 0.162 billion yuan and 14.1448 million yuan in assets.

cls.cnNov 22 11:06 ET

No money again! Shenzhen Chipscreen Biosciences has "burned" 0.9 billion in R&D expenses over three years and plans to raise another 0.96 billion, nearly 30% of which will be used to supplement cash flow.

shenzhen chipscreen biosciences announced a plan for private placement, planning to raise 0.96 billion yuan, with 0.71 billion yuan for innovative drug research and development, and 0.25 billion yuan for supplementary working capital, reaching a replenishment ratio of 26.04%; Multiple research pipelines continue to burn money for shenzhen chipscreen biosciences, with a total research and development expense of 0.927 billion yuan from 2021 to 2023, currently 17 indication pipelines are in clinical trial stage.

cls.cnNov 21 04:55 ET

Star Evening News | kbc corporation,ltd. affiliated companies' silicon-based anode series products have formed bulk supply. shenzhen chipscreen biosciences plans to raise no more than 0.96 billion yuan through a private placement.

1. Polymax Materials' shareholder plans to reduce its shareholding by no more than 3% of the company's shares; 2. Micronano intends to repurchase shares ranging from 40 million yuan to 80 million yuan; 3. Beijing Hotgen Biotech Co.,Ltd. plans to repurchase shares at a range of 58 million yuan to -0.1 billion yuan; 4. Suzhou Hyc Technology plans to repurchase shares at a range of 25 million yuan to -50 million yuan.

cls.cnNov 20 07:56 ET

Subsidiary's slow R&D progress questioned, zhejiang huahai pharmaceutical responds: 'More than 10 products have entered the clinical research stage' | Direct hit on earnings conference

①At the earnings conference, zhejiang huahai pharmaceutical's research and development pipeline progress was questioned by investors. In response, the company's secretary to the board, Zhu Yonghua, provided an overview of the pipeline under development. ②On the zhejiang huahai pharmaceutical side, due to various factors such as the growth of key original research customers, revenue from active pharmaceutical ingredients and formulations business has increased in the first three quarters of this year.

cls.cnNov 20 05:45 ET